261 related articles for article (PubMed ID: 11008249)
21. [Should adjuvant chemotherapy be also used in Dukes stage B2 colon cancer?].
Porschen R
Z Gastroenterol; 1996 Sep; 34(9):549-51. PubMed ID: 8975491
[No Abstract] [Full Text] [Related]
22. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer.
Zuckerman IH; Rapp T; Onukwugha E; Davidoff A; Choti MA; Gardner J; Seal B; Mullins CD
J Am Geriatr Soc; 2009 Aug; 57(8):1403-10. PubMed ID: 19563521
[TBL] [Abstract][Full Text] [Related]
23. [Chemotherapy of colonic carcinoma in the year 2001].
Mross K; Semsek D
Praxis (Bern 1994); 2001 Mar; 90(12):497-510. PubMed ID: 11324309
[TBL] [Abstract][Full Text] [Related]
24. Effects of 5-fluorouracil adjuvant treatment of colon cancer.
Kelder W; Hospers GA; Plukker JT
Expert Rev Anticancer Ther; 2006 May; 6(5):785-94. PubMed ID: 16759168
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer.
Sobrero A; Frassineti G; Falcone A; Dogliotti L; Rosso R; Di Costanzo F; Bruzzi P;
Br J Cancer; 2005 Jan; 92(1):24-9. PubMed ID: 15611795
[TBL] [Abstract][Full Text] [Related]
26. [Adjuvant therapy for colon cancer].
Moiseenko VM; Orlova RV
Vopr Onkol; 1998; 44(6):741-5. PubMed ID: 10087982
[No Abstract] [Full Text] [Related]
27. [Adjuvant therapy for colon cancer].
Lordick F; Rosenberg R; Stein HJ; Peschel C; Siewert JR
Dtsch Med Wochenschr; 2004 Oct; 129(44):2366-71. PubMed ID: 15497107
[No Abstract] [Full Text] [Related]
28. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.
Benson AB; Schrag D; Somerfield MR; Cohen AM; Figueredo AT; Flynn PJ; Krzyzanowska MK; Maroun J; McAllister P; Van Cutsem E; Brouwers M; Charette M; Haller DG
J Clin Oncol; 2004 Aug; 22(16):3408-19. PubMed ID: 15199089
[TBL] [Abstract][Full Text] [Related]
29. Final results of randomized trials by the National Surgical Adjuvant Study of Colorectal Cancer (NSAS-CC).
Hamaguchi T; Shirao K; Moriya Y; Yoshida S; Kodaira S; Ohashi Y;
Cancer Chemother Pharmacol; 2011 Mar; 67(3):587-96. PubMed ID: 20490797
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant therapy in stage II colon cancer: current approaches.
Baddi L; Benson A
Oncologist; 2005 May; 10(5):325-31. PubMed ID: 15851790
[No Abstract] [Full Text] [Related]
33. New approaches to the adjuvant therapy of colon cancer.
Benson AB
Oncologist; 2006 Oct; 11(9):973-80. PubMed ID: 17030637
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III.
Taal BG; Van Tinteren H; Zoetmulder FA;
Br J Cancer; 2001 Nov; 85(10):1437-43. PubMed ID: 11720425
[TBL] [Abstract][Full Text] [Related]
35. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
Lembersky BC; Wieand HS; Petrelli NJ; O'Connell MJ; Colangelo LH; Smith RE; Seay TE; Giguere JK; Marshall ME; Jacobs AD; Colman LK; Soran A; Yothers G; Wolmark N
J Clin Oncol; 2006 May; 24(13):2059-64. PubMed ID: 16648506
[TBL] [Abstract][Full Text] [Related]
36. Young age influences treatment but not outcome of colon cancer.
Quah HM; Joseph R; Schrag D; Shia J; Guillem JG; Paty PB; Temple LK; Wong WD; Weiser MR
Ann Surg Oncol; 2007 Oct; 14(10):2759-65. PubMed ID: 17593332
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment.
Kornmann M; Formentini A; Ette C; Henne-Bruns D; Kron M; Sander S; Baumann W; Kreuser ED; Staib L; Link KH
Eur J Surg Oncol; 2008 Dec; 34(12):1316-21. PubMed ID: 18313881
[TBL] [Abstract][Full Text] [Related]
38. Innovative chemotherapies for stage III colon cancer: a cost-effectiveness study.
Koperna T; Semmler D
Hepatogastroenterology; 2003; 50(54):1903-9. PubMed ID: 14696430
[TBL] [Abstract][Full Text] [Related]
39. Clinical overview: adjuvant therapy of gastrointestinal cancer.
Macdonald JS
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S4-11. PubMed ID: 15309508
[TBL] [Abstract][Full Text] [Related]
40. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
Dahl O; Fluge Ø; Carlsen E; Wiig JN; Myrvold HE; Vonen B; Podhorny N; Bjerkeset O; Eide TJ; Halvorsen TB; Tveit KM;
Acta Oncol; 2009; 48(3):368-76. PubMed ID: 19242829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
